StockData
GENELUX Corp logo

GENELUX Corp (GNLX) stock

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.00+0.08 (+4.17%)

Close on Nov 17, 2026Market cap $90.49MP/E –Yield –

Genelux r&d expenses

Research and development expenses are spending on new products and technology.

Genelux's R&D Expenses for the twelve months ending Jun 30, 2026 was $22.68M, up 13.3% year over year. For fiscal 2025 it was $19.85M, up 4.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.85M+4.5%
FY2024Dec 31, 2024$19.00M+48.8%
FY2023Dec 31, 2023$12.77M+40.6%
FY2022Dec 31, 2022$9.08M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.51M+36.8%
Q1 FY2026Mar 31, 2026$5.78M+23.0%
Q4 FY2025Dec 31, 2025$5.65M-13.3%
Q3 FY2025Sep 30, 2025$4.74M+17.0%
Q2 FY2025Jun 30, 2025$4.76M+7.7%
Q1 FY2025Mar 31, 2025$4.70M+17.2%
Q4 FY2024Dec 31, 2024$6.52M+56.7%
Q3 FY2024Sep 30, 2024$4.05M+43.7%
Q2 FY2024Jun 30, 2024$4.42M+50.1%
Q1 FY2024Mar 31, 2024$4.01M+40.9%
Q4 FY2023Dec 31, 2023$4.16M+68.6%
Q3 FY2023Sep 30, 2023$2.82M+16.8%
Q2 FY2023Jun 30, 2023$2.94M+61.1%
Q1 FY2023Mar 31, 2023$2.85M+20.1%
Q4 FY2022Dec 31, 2022$2.47M–
Q3 FY2022Sep 30, 2022$2.41M–
Q2 FY2022Jun 30, 2022$1.83M–
Q1 FY2022Mar 31, 2022$2.37M–

More Genelux figures

See a number that looks wrong?